This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Experimental evaluation of the activity of the product meflochine against coronavirus SАRS-CoV-2
1 Federal State Unitary Enterprise Research & Production Center "Pharmaceutical Protection" of Federal Medical Biological Agency, Khimki, Russia
2 Federal Medical and Biological Agency, Moscow, Russia
3 Federal State Budgetary Institution "48 Central Research Institute" of the Ministry of Defense of the Russian Federation, Sergiev Posad-6, Russia
When evaluating the effectiveness of the drug Mefloquine against SARS-CoV-2 coronavirus, in vitro experiments examined its toxicity for African green monkey kidney cell culture - Vero C1008, as well as antiviral activity against SARS-CoV-2, which was evaluated by suppressing the cytopathic effect the virus.
A study of the toxicity of the drug Mefloquine showed that the concentration at which the drug exerts a cytopathic effect against 50% of Vero C1008 cells is 4.5 μg / ml. The maximum tolerated concentration (MTD) of Mefloquine is 2.25 μg / ml.
A study of the effectiveness showed that 1 day after infection, the antiviral effect of Mefloquine was recorded when the drug was added 24 hours and 1 hour before infection with SARS-CoV-2, as well as when it was added 1 hour after infection, the cell culture was already at a concentration of 0.5 μg / ml Mefloquine at a concentration of 2 μg / ml, added to the Vero C1008 cell culture 1 hour after the introduction of SARS-CoV-2, completely blocked the action of the virus for 2 days after infection.
Keywords: coronavirus, COVID-19, SARS-CoV-2, antiviral activity, mefloquine